ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Rare Disease Therapeutics, Inc. Announces New Expanded FDA Approved Indication for Antivenom ANAVIP® for Treatment of North American Pit Viper Envenomation
April 07, 2021Rare Disease Therapeutics, Inc. (RDT) announced that the United States (US) Food & Drug Administration (FDA) approved a new expanded indication for ANAVIP® (crotalidae immune F(ab’)2 (equine)), an equine-derived antivenin, for the management of adult ... -
Rare Disease Therapeutics Introduces New Antivenom for Rattlesnake Bites
October 12, 2018Rare Disease Therapeutics (RDT) announced the launch of ANAVIP [Crotalidae Immune F(ab') (Equine)] an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.
Pharma Sources Insight January 2025
